Intelligence·9 min read·

The UAE Built an Ocean of Pharmaceutical Supply Chain Data. The Next Step Is Using It

Most UAE distributors already own the data to cut stock-outs, find cold-chain weak points and forecast demand — from Tatmeen serialisation, temperature logs and inspections. How to turn compliance data into supply chain intelligence.

V-Sentinel Editorial · Healthcare supply chain compliance, GCC

Most pharmaceutical distributors in the UAE already own the data they would need to cut stock-outs, find their cold-chain weak points, and forecast demand more accurately. The problem was never collecting it. It is using it.

Every pack of prescription medicine that moves through the country now leaves a digital trail — scanned into Tatmeen at manufacture or import, aggregated into cartons and pallets, and scanned again as it changes hands. Add the temperature logs from every qualified cold room, the records behind several hundred warehouse inspections a year, and the electronic dossiers behind every registered product, and the UAE has an unusually detailed view of how medicine moves across its supply chain. Almost all of that data was generated to prove compliance. Its more valuable second life is as operational intelligence — and most of it is currently sitting unused.

A caution before the optimism: data accumulation does not, by itself, create insight. Quality, integration and governance decide whether a warehouse of records becomes a source of foresight or stays an archive. What follows is an opportunity to do work, not a dividend that arrives on its own. But the raw material already exists in your building, the capability to use it now exists in the country, and the firms that start treating compliance data as an asset will pull ahead of those that keep treating it as an obligation.

The data you already own — and how unusually centralised it is

Tatmeen, the UAE's national track-and-trace platform, went live in December 2022 under a Ministry of Health and Prevention mandate, built on GS1 global standards and operated on EVOTEQ's technology.1 It records serialisation, aggregation and event-based movement for covered medicinal products, from the manufacturing line to the point of dispensing. The volumes are not trivial: as of early 2024 the platform had recorded more than 280 million traceability transactions and over 67 million scanned parcels, and it has continued to grow since.2

What makes the UAE position distinctive is less the existence of the data — unit-level serialisation is increasingly common across regulated pharmaceutical markets — and more how centralised it is. The UAE is not alone in the ambition: Turkey's İTS pioneered national track-and-trace as far back as 2012, and Saudi Arabia's SFDA runs the centralised Rassd (RSD) system.3 But in many markets traceability data remains distributed across competing private platforms and ledgers, and the UAE has pursued a notably centralised approach by comparison. Centralisation is what makes national-scale pattern-finding possible rather than merely theoretical — though, as above, only where the underlying data is clean and connected.

What that data does elsewhere — and who is already doing it

Serialisation data has already proven its second life, and not only in principle. In the United States, the Drug Supply Chain Security Act has built unit-level traceability into national distribution.4 In Europe, the Medicines Verification System created to block falsified medicines has been openly recognised — by industry bodies including EFPIA — as a wealth of intelligence on how medicines actually flow, usable for purposes beyond its original anti-counterfeit design, shortage avoidance among them.5 And since February 2025 the European Medicines Agency's European Shortages Monitoring Platform has made supply, demand and availability reporting mandatory across the EU, turning availability data into an early-warning system for shortages.5

The UAE generates structurally the same data. The uses pioneered elsewhere — recall scope found in minutes rather than weeks, anomaly and diversion detection, demand sensing, and distribution planned against real movement rather than forecast alone — are therefore available to it, with the advantage of the central visibility that several of those markets had to assemble piece by piece.

The capability to use it is already in the country

None of this requires importing expertise. In April 2026 a UAE-based team at Insilico Medicine, working in collaboration with the EDE, nominated a compound designated ISM0387 — described as the UAE's first fully AI-discovered and developed drug candidate, designed for an aggressive brain cancer using a generative-AI platform that generated and tested more than ninety molecules in roughly six months.6 Drug discovery and supply-chain analytics are different disciplines, and being able to do one does not by itself confer readiness in the other. But the example demonstrates the depth of AI capability now resident in the UAE ecosystem — alongside the Mohamed bin Zayed University of Artificial Intelligence and the Cabinet's Regulatory Intelligence Ecosystem applying AI to lawmaking.7 The talent to turn data into decisions is in the country.

The regulator has signalled the same intent on its side, stating that it will expand its use of digital tools and data analytics to strengthen oversight and support market stability.8 Read together with the National Strategy for Artificial Intelligence 2031, the more practical question is not whether this data eventually gets used, but how quickly individual organisations begin extracting value from what is already available to them.9

What a distributor can do with it now

The value does not depend on what the regulator eventually builds. The same Tatmeen events, temperature histories and throughput records you generate for compliance already describe the things a supply chain director most wants to know. Read as intelligence rather than as archive, they show where the cold chain runs closest to its limits before an excursion happens, which lines move fast enough to tighten stock against, where returns cluster and why, and which products carry the most shortage risk — the kind of early warning that matters most when a demand wave like the obesity-drug surge tightens supply. The pay-off is concrete and commercial: fewer excursions, less wastage, leaner inventory, better service levels, and earlier warning of disruption.

A useful way to gauge how far an operation already is from that position is to put three questions to its own data:

  1. Can you identify your highest-risk temperature zones — the specific locations and times of day where excursions are most likely — from your own monitoring history?
  2. Can you see a stock-out forming before it happens, from your own movement and demand data?
  3. Can you trace a product's movement across your network, end to end, within minutes rather than days?

An operation that can answer all three is already running on intelligence. One that cannot almost certainly has the data to get there; it is a question of organising and using it, not acquiring it. If the underlying GDP and inspection readiness is already in order, the data quality needed for analytics is largely there too.

A question worth settling early: who owns the data

As these systems mature, one question grows in importance: who owns the data, and who may use it. Serialisation events touch the manufacturer, the distributor, the platform operator and the regulator at once; temperature and throughput records are commercially sensitive; and the line between regulatory visibility and competitive intelligence is not always obvious. Governance, ownership and access are becoming as consequential as the technology itself, and they are better settled deliberately — in contracts and data policy — than left to default. The operators who think this through early will have more freedom to use their own data than those who do not.

The regulator is moving in the same direction, though for a distributor that is the smaller part of the story. The consistency of your serialisation and temperature records increasingly contributes to how an operation is assessed during regulatory interactions and inspections — a good reason to keep the data clean quite apart from its commercial use. But the larger prize sits in your own hands, not the regulator's.

The shift is one of posture

The change required is not technological so much as a change of stance: from data filed to prove the past, to data read to anticipate the future. The infrastructure is already in your building, the capability is already in the country, and the uses are already proven elsewhere. What remains is the decision to look at what you already have. For most UAE distributors, this asset is not something to acquire. It is something to start using.

V-Sentinel helps UAE distributors and 3PLs turn compliance data into supply chain foresight — fewer excursions, leaner stock, earlier warning of disruption. Use our GDP Readiness Assessment to see where your operation stands. Senior expert review, AI-powered delivery.

Sources

Footnotes

  1. Tatmeen (UAE national track-and-trace platform), About / Platform Overview (launched December 2022 under MOHAP Ministerial Decree No. 73 of 2021; GS1 standards; operated on EVOTEQ technology), tatmeen.ae; corroborated by industry serialisation briefings (CosmoTrace, SoftGroup). ↩

  2. Serialisation industry reporting on Tatmeen adoption (more than 280 million traceability transactions and over 67 million scanned parcels recorded as of early 2024), CosmoTrace, blog.cosmotrace.com. Figures are the latest publicly reported at time of writing and have grown since. ↩

  3. Global Health: Science and Practice, What Makes a National Pharmaceutical Track and Trace System Succeed? Lessons From Turkey (Turkey's İTS, full national track-and-trace from 2012), ghspjournal.org; Saudi Food and Drug Authority, RSD (Rassd) national track-and-trace system, sfda.gov.sa. ↩

  4. U.S. Food and Drug Administration, Drug Supply Chain Security Act (DSCSA), fda.gov. ↩

  5. EFPIA, Using the FMD Data Repositories for Shortages Monitoring (European Medicines Verification System recognised as supply-chain intelligence beyond its anti-falsification purpose), efpia.eu; European Medicines Agency, European Shortages Monitoring Platform (ESMP) (mandatory for marketing authorisation holders and national competent authorities from 2 February 2025), ema.europa.eu. ↩ ↩2

  6. Gulf News / Khaleej Times, UAE unveils its first fully AI-discovered, developed cancer drug candidate (ISM0387; Insilico Medicine UAE team with the EDE; Chemistry42 generative-AI platform; 90+ molecules in roughly six months; April 2026), gulfnews.com / khaleejtimes.com. ↩

  7. UAE Cabinet / General Secretariat of the Cabinet, UAE Cabinet approves the launch of the first integrated Regulatory Intelligence Ecosystem (April 2025), uaecabinet.ae; Mohamed bin Zayed University of Artificial Intelligence, mbzuai.ac.ae. ↩

  8. Gulf News / Zawya, Emirates Drug Establishment conducts over 568 inspections since start of year (inspection findings integrated into central digital systems; stated intent to expand digital tools and data analytics to strengthen oversight and support market stability), gulfnews.com / zawya.com. ↩

  9. UAE Government, UAE National Strategy for Artificial Intelligence 2031, u.ae. ↩

← Back to Insights